Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Description

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.

Conditions

Hematologic Malignancy

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.

Mechanisms of Disease Relapse/Resistance in CAR T Therapy for Hematologic Malignancies

Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies

Condition
Hematologic Malignancy
Intervention / Treatment

-

Contacts and Locations

Durham

Duke University, Durham, North Carolina, United States, 27710

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.
  • 2. Has a confirmed diagnosis of hematologic malignancy and will be undergoing CAR T therapy with commercial CAR T product.
  • 3. Patient who has a confirmed diagnosis of hematologic malignancy and will be receiving CAR T therapy under clinical trial protocol will also be eligible if the clinical trial sponsor and the investigator approve patient participation in the study.
  • * NA

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Duke University,

Yubin Kang, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

2025-11-01